Emerald Science, a Californian company developing medical cannabis has opened its first office in Australia, paving the way for the first human study of NB1111, the prodrug of THC, for the treatment of glaucoma.

Emerald Science CEO Dr Brian Murphy said, “We are pleased with our progress in moving our drug candidate projects forward both in ophthalmology and potentially in diseases that affect other organ systems. The Australian office will serve as a key gateway for our future clinical studies with NB1111 and CBDVHS.”

The company reported its proprietary analog of cannabidiol, cannabidiol-valine-hemisuccinate, is ready for pre-clinical studies. These studies will complement those published by the University of Mississippi, demonstrating a nanoemulsion formulation of CBDVHS penetrated both the anterior and posterior chambers of the eye, including the neurological cells that comprise the retina.